Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 5/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5965361 | 1.00 | KMT2A (0.51) | KMT2AACEMEN1DRD2DRD4 | |
| SCHEMBL27548369 | 0.89 | KMT2A (0.51) | KMT2AACEMEN1DRD2DRD4 | |
| SCHEMBL8905911 | 0.84 | KMT2A (0.47) | KMT2AACEMEN1DRD2DRD4 | |
| SCHEMBL29443080 | 0.83 | KMT2A (0.46) | KMT2AACEMEN1DRD2DRD4 | |
| SCHEMBL21490396 | 0.83 | KMT2A (0.46) | KMT2AACEMEN1DRD2DRD4 | |
| SCHEMBL6193812 | 0.83 | POLB (0.52) | KMT2AACEMEN1TSHR | |
| SCHEMBL17559114 | 0.82 | MTNR1A (0.54) | KMT2AACEMEN1MTNR1ATSHR | |
| SCHEMBL27466432 | 0.82 | KMT2A (0.47) | KMT2AACEMEN1MTNR1ATSHR | |
| SCHEMBL27483252 | 0.82 | KMT2A (0.47) | KMT2AACEMEN1MTNR1ATSHR | |
| SCHEMBL6625409 | 0.81 | KMT2A (0.46) | KMT2AACEMEN1MTNR1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053057-B2 | A carbamate and amide compound containing piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; enzyme inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1283827-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-02-19 | — | — | EP | disclosed |
| US-20020061853-A1 | Caspase inhibtors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-05-23 | — | — | US | disclosed |
| WO-2001090070-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061853-A1 | Caspase inhibtors and uses thereof | CASP2, CASP1, CASP3 | KMT2A 3538/4885ACE 1000/4885MEN1 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.